Moderna, Inc. ADR (MRNA)

Overview

Moderna, Inc. is a pioneering biotechnology firm that has dedicated itself to the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. This innovative approach is aimed at combating a wide range of diseases, including infectious diseases, immuno-oncology conditions, rare diseases, autoimmune disorders, and cardiovascular diseases. The company's operations extend across the United States, Europe, and several international markets. Since its foundation in 2010 and subsequent renaming from Moderna Therapeutics, Inc. in August 2018, Moderna has been headquartered in Cambridge, Massachusetts. It has forged strategic alliances and collaborations with industry giants and research institutions such as AstraZeneca, Merck & Co., Inc., Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., Metagenomi, Inc., and the Bill & Melinda Gates Foundation, among others. These partnerships have been vital in driving forward Moderna's mission of leveraging mRNA technology to create a new generation of transformative medicines.

Products and Services

• Respiratory Vaccines: Moderna's portfolio includes vaccines against COVID-19, influenza, and the respiratory syncytial virus, along with Spikevax, and hMPV/PIV3 vaccines. These products represent significant advances in the prevention of respiratory diseases.
• Latent Vaccines: This category features vaccines for latent viruses such as cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and HIV. Such vaccines are crucial in the fight against persistent viral infections.
• Public Health Vaccines: Moderna is also developing vaccines for Zika, Nipah, and Mpox viruses, focusing on lesser-known yet impactful public health threats.
• Infectious Diseases Vaccines: This area includes the development of vaccines for Lyme disease and norovirus, targeting infectious diseases with significant public health importance.
• Systemic Secreted and Cell Surface Therapeutics: Besides vaccines, Moderna is working on therapeutics that are systemically delivered to address a variety of diseases, showcasing the versatility of mRNA technology.
• Cancer Vaccines: The company's oncology segment includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines, aiming at harnessing the body's immune response to target and eliminate cancer cells.
• Intratumoral Immuno-Oncology Products: These are designed for direct injection into tumors to stimulate an immune response locally, offering a novel approach to cancer treatment.
• Rare Disease Intracellular Therapeutics: Moderna is developing treatments for rare diseases by targeting intracellular mechanisms, potentially addressing conditions with unmet medical needs.
• Inhaled Pulmonary Therapeutics: Exploiting the potential of mRNA technology for diseases affecting the lungs, these therapeutics are administered via inhalation.